Mereo BioPharma Group (MREO) Projected to Release Earnings on Monday

Mereo BioPharma Group (NASDAQ:MREO) will likely be releasing its Q3 2026 resultson Monday, November 9th. Analysts expect Mereo BioPharma Group to post earnings of ($0.01) per share and revenue of $4.61 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 2:00 AM ET.

Mereo BioPharma Group (NASDAQ:MREO) last posted its earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). On average, analysts expect Mereo BioPharma Group to post ($0.04) EPS for the current fiscal year and ($0.03) EPS for the next fiscal year.

Mereo BioPharma Group Stock Performance

Shares of NASDAQ:MREO opened at $0.29 on Monday. Mereo BioPharma Group has a 12-month low of $0.20 and a 12-month high of $2.37. The business has a 50 day moving average of $0.31 and a two-hundred day moving average of $0.34. The company has a market capitalization of $46.23 million, a PE ratio of -7.24 and a beta of 0.29.

Analyst Ratings Changes

MREO has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mereo BioPharma Group in a research note on Tuesday, September 29th. Needham & Company LLC reiterated a “buy” rating on shares of Mereo BioPharma Group in a research report on Tuesday, August 11th. JPMorgan Chase & Co. cut Mereo BioPharma Group from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 19th. Finally, BTIG Research restated a “buy” rating and set a $1.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $1.67.

About Mereo BioPharma Group

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology. The company’s research programs are intended to address conditions with significant unmet medical needs, using biologic and small-molecule drug candidates.

Mereo’s lead program is setrusumab, an investigational monoclonal antibody designed to inhibit sclerostin and stimulate bone formation. The therapy is being developed for osteogenesis imperfecta, a rare genetic disorder characterized by fragile bones, through a collaboration with Ultragenyx Pharmaceutical.